Just read this whilst i wait for my cab to go into the city for dinner.
Good post by a2g re sample sizes required in a prospective study to get a meaningful sample of CIN2+ that can result in a statistically significant data set.
I'll need to look into it further but my understanding is that the RWH samples are not from a screeing poplulation but were ASCUS and hence one should see a far higher proportion of CIN2+ samples (on a % basis)
ASCUS was the route that Digene followed in getting HC2 approved by the FDA.
That being said I do not think that the current GBI study could be relevant to any FDA submission but only to a CE Mark/TGA approval.
Oh cabs here will follow this up later tonight/tomorrow
Good posts by all here and of high quality. keep it up everyone!
- Forums
- ASX - By Stock
- GBI
- hpv genotyping trial design
hpv genotyping trial design, page-3
-
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GBI (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SS1
SUN SILVER LIMITED
Gerard O'Donovan, Executive Director
Gerard O'Donovan
Executive Director
SPONSORED BY The Market Online